Aclasta/Actonel Class Action | Action collective Aclasta/Actonel

NOTICE OF DISCONTINUANCE OF A CLASS ACTION

CLICK HERE FOR NOTICE DOCUMENT

CLICK HERE FOR JUDGMENT DOCUMENT

TAKE NOTICE that on January 25, 2017, the Honorable Justice Pierre-C. Gagnon of the Superior Court authorized the discontinuance of a proposed class action.

The Petitioner was seeking to represent the two proposed groups described below:

“All persons in Canada (including their estates, executors, personal representatives, their dependants and family members), who were prescribed, purchased, used or ingested any Bisphosphonate drugs, including but not limited to the brand name Actonel, manufactured, marketed or distributed by Respondents Procter & Gamble Pharmaceuticals Canada Inc., Procter & Gamble Pharmaceuticals inc., the Procter & Gamble Company, Warner Chilcott Canada Co., Warner Chilcott Pharmaceuticals Inc. and Warner Chilcott PLC and/or any other related companies, or any other Group or Sub-Group to be determined by the Court

All persons in Canada (including their estates, executors, personal representatives, their dependants and family members), who were prescribed, purchased, used or ingested any Bisphosphonate drugs, including but not limited to the brand name Aclasta, manufactured, marketed or distributed by Respondents Novartis Pharma Canada Inc., Novartis Pharmaceuticals Corp., Novartis International AG and/or any other related companies, or any other Group or Sub-Group to be determined by the Court”

By reason of the discontinuance the operation of Article 2908 of the Civil Code of Quebec has ceased and prescription has started to run again. Please take this change into account if you wish to institute court proceedings against one of the respondents in relation to the products Actonel or Aclasta.

This notice has been approved by the court.

AVIS DE DÉSISTEMENT D’UNE ACTION COLLECTIVE

cliquez ici pour NOTICE DOCUMENT

cliquez ici pour JUDGMENT DOCUMENT

PRENEZ AVIS que le 25 janvier 2017, l’honorable juge Pierre-C. Gagnon de la Cour supérieure a autorisé le désistement d’une demande d’autorisation d’action collective.

La Requérante demandait à représenter les deux groupes proposés et décrits ci-après, à savoir :

“All persons in Canada (including their estates, executors, personal representatives, their dependants and family members), who were prescribed, purchased, used or ingested any Bisphosphonate drugs, including but not limited to the brand name Actonel, manufactured, marketed or distributed by Respondents Procter & Gamble Pharmaceuticals Canada Inc., Procter & Gamble Pharmaceuticals inc., the Procter & Gamble Company, Warner Chilcott Canada Co., Warner Chilcott Pharmaceuticals Inc. and Warner Chilcott PLC and/or any other related companies, or any other Group or Sub-Group to be determined by the Court

All persons in Canada (including their estates, executors, personal representatives, their dependants and family members), who were prescribed, purchased, used or ingested any Bisphosphonate drugs, including but not limited to the brand name Aclasta, manufactured, marketed or distributed by Respondents Novartis Pharma Canada Inc., Novartis Pharmaceuticals Corp., Novartis International AG and/or any other related companies, or any other Group or Sub-Group to be determined by the Court”

En raison du désistement, les effets de l’article 2908 du Code civil du Québec ont cessé et le délai de prescription a recommencé à courir. Veuillez tenir compte de ce changement si vous entendez instituer une poursuite judiciaire contre l’un des intimés en relation avec les produits Actonel ou Aclasta.

Cet avis a été approuvé par la cour.